advertisement
Abstract #94447 Published in IGR 22-2
Canaloplasty and trabeculotomy ab interno with the OMNI system combined with cataract surgery in open-angle glaucoma: 12-month outcomes from the ROMEO study
Hirsch L; Cotliar J; Vold S; Selvadurai D; Campbell A; Ferreira G; Aminlari A; Cho A; Heersink S; Hochman M; Gallardo M; Williamson B; Phan R; Nelson C; Dickerson JEJournal of Cataract and Refractive Surgery 2021; 47: 907-915
PURPOSE: To provide safety and effectiveness outcomes 12 months postsurgically for sequential canaloplasty and trabeculotomy with the OMNI system combined with cataract surgery in mild-to-moderate open-angle glaucoma (OAG). SETTING: Eleven ophthalmology practices and surgery centers located in 8 U.S. states. DESIGN: Retrospective, multicenter, single arm. METHODS: Twelve surgeons contributed 81 patients meeting eligibility criteria: OAG, 12-month follow-up, and medicated intraocular pressure (IOP) 36 mm Hg or less on 4 or less medications preoperatively. Analysis was stratified by baseline IOP: more than 18 mm Hg (Group 1) and 18 mm Hg (Group 2) or less. Success was defined as proportion with 20% reduction or greater in IOP or IOP between 6 and 18 mm Hg (inclusive) and on the same or fewer medications without secondary surgical intervention (SSI). Other endpoints included mean IOP and medications at 12 months. Safety included corrected distance visual acuity and adverse events (AEs). RESULTS: Of the 81 patients included, primary success was met by 79% in Group 1 and 81% in Group 2. The mean IOP was reduced in Group 1 (21.9 to 15.1 mm Hg, P < .0001) and remained controlled in Group 2 (14.1 to 13.4 mm Hg, P = .3177). Medications went from 2.0 ± 1.3 to 1.1 ± 1.1 in Group 1 and from 1.6 ± 1.3 to 0.9 ± 1.2 in Group 2. AEs were typical for cataract or angle surgery: mild inflammation (11%), IOP spikes (5%), and hyphema (4%). Four patients (5%) required an SSI. CONCLUSIONS: The OMNI system provided effective IOP reduction, sustained IOP control, and meaningful medication reduction for up to 12 months postoperative.
From the Mercy Eye Specialists, Springfield, Missouri (Hirsch); Columbia University Medical Center, New York, New York (Cotliar); Arthur M Cotliar Eye Care and Surgery, New York, New York (Cotliar, Ferreira); Vold Vision, Fayetteville, Arkansas (Vold); Ophthalmology Associates of Western New York, Williamsville, New York (Selvadurai); Grene Vision Group, Wichita, Kansas (Campbell); Morris Eye Group, Encinitas, California (Aminlari); Serrano Eye Center Medical Group, Los Angeles, California (Cho); Eye Center South, Dothan, Alabama (Heersink); private practice, Laredo, Texas (Hochman); El Paso Eye Surgeons, PA, El Paso, Texas (Gallardo); Department of Ophthalmology, University of Texas Health Sciences Center, San Antonio, Texas (Gallardo); The Williamson Eye Center, Baton Rouge, Louisiana (Williamson, Nelson); Nassau University Medical Center, East Meadow, New York (Phan); North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, Texas (Dickerson); Sight Sciences, Inc, Menlo Park, California (Dickerson).
Full articleClassification:
12.14.3 Phacoemulsification (Part of: 12 Surgical treatment > 12.14 Combined cataract extraction and glaucoma surgery)
12.9 Trabeculotomy, goniotomy (Part of: 12 Surgical treatment)
